INHIBITORS OF INFLUENZA VIRUSES REPLICATION

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: WANG, Tiansheng, LEDEBOER, Mark, W, LEDFORD, Brian, WANNAMAKER, M., Woods, BANDARAGE, Upul, K, DUFFY, John, P, LIN, Chao, GERMANN, Ursula, A, SALITURO, Francesco G, COURT, John, J, GAO, Huai, KENNEDY, Joseph, M, CLARK, Michael, P, MALTAIS, Francois, JONES, Steven, KWONG, Ann Dak-Yee, JACOBS, Dylan, H, GU, Wenxin, PEROLA, Emanuele, FARMER, Luc, BYRN, Randal, DENG, Hongbo, ZHOU, Yi, CHARIFSON, Paul, JIANG, Min, DRUTU, Ioana, BETHIEL, Randy, S
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula ( I ): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula ( IA ) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula ( IA ) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.